Molnupiravir

Molnupiravir

Molnupiravir chemical structure

Molnupiravir is an antiviral medication that is used to treat COVID-19. It was developed by the pharmaceutical companies Merck & Co. and Ridgeback Biotherapeutics. Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action by introducing errors into the viral RNA during replication.

Mechanism of Action

Molnupiravir works by incorporating itself into the viral RNA. Once inside the viral RNA, it causes mutations during the replication process. These mutations accumulate and lead to "error catastrophe," which reduces the ability of the virus to replicate and spread.

Molnupiravir metabolism

The drug is metabolized into its active form, N4-hydroxycytidine, which is then phosphorylated to the active triphosphate form. This active form is incorporated into the viral RNA by the viral RNA-dependent RNA polymerase.

Chemical Properties

Molnupiravir is a prodrug, meaning it is metabolized in the body to become an active pharmacological agent. Its chemical structure allows it to mimic the natural nucleosides used by the virus to replicate its RNA.

Synthesis

Molnupiravir synthesis

The synthesis of molnupiravir involves several chemical reactions starting from uridine, a naturally occurring nucleoside. The process includes the introduction of a hydroxylamine group to form N4-hydroxycytidine, which is then converted into molnupiravir.

Bonding and Interaction with Viral RNA

Molnupiravir GC bonding

Molnupiravir can pair with both guanine and adenine, leading to G-to-A and C-to-U transitions in the viral genome. This dual pairing ability is crucial for its mechanism of inducing lethal mutagenesis in the virus.

Molnupiravir AU bonding

Clinical Use

Molnupiravir is administered orally and is used in the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. It is typically prescribed for patients who cannot receive other treatments or for whom other treatments are not appropriate.

Safety and Efficacy

Clinical trials have shown that molnupiravir can reduce the risk of hospitalization and death in patients with COVID-19. However, its use is subject to ongoing evaluation, and it is important to consider potential side effects and contraindications.

Related Pages

• COVID-19 pandemic
• Antiviral drug
• RNA virus
• Merck & Co.

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B Inhibitors (Polymerase inhibitors)

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus

• infections (HSV), CMV, others

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir